Octreotide detrimental to glucose metabolism in acromegaly

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1346, 2002-01, pp. : 15-15

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Octreotide for acromegaly treatment: a reappraisal

By Giustina Andrea Karamouzis Ioannis Patelli Ilaria Mazziotti Gherardo

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 17, 2013-12 ,pp. : 2433-2447

Informa Healthcare

Access to resources Recommend Favorite

Pegvisomant modulates cortisol metabolism in acromegaly

Inpharma, Vol. 1, Iss. 1302, 2001-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Octreotide Long-Acting Release (LAR): A Review of its Use in the Management of Acromegaly

By Yang Lily P.H. Keating Gillian M.

Drugs, Vol. 70, Iss. 13, 2010-09 ,pp. : 1745-1769

Adis International

Access to resources Recommend Favorite

Octreotide Long-Acting Release (LAR): A Review of its Use in the Management of Acromegaly

By McKeage K. Cheer S. Wagstaff A.J.

Drugs, Vol. 63, Iss. 22, 2003-01 ,pp. : 2473-2499

Adis International

Access to resources Recommend Favorite

Glucose Metabolism and Antidepressant Medication

Current Pharmaceutical Design, Vol. 18, Iss. 36, 2012-12 ,pp. : 5900-5919

Bentham Science Publishers

Access to resources Recommend Favorite